Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.

Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr.

J Immunother Cancer. 2019 Jun 27;7(1):163. doi: 10.1186/s40425-019-0625-x.

2.

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Slingluff CL Jr.

Cancer Immunol Immunother. 2019 Jul;68(7):1121-1132. doi: 10.1007/s00262-019-02345-5. Epub 2019 May 27.

PMID:
31134297
3.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr.

Oncoimmunology. 2016 Oct 18;5(12):e1240857. doi: 10.1080/2162402X.2016.1240857. eCollection 2016.

4.

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL.

Oncoimmunology. 2016 Sep 20;5(11):e1235107. doi: 10.1080/2162402X.2016.1235107. eCollection 2016.

5.

Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.

Obeid JM, Wages NA, Hu Y, Deacon DH, Slingluff CL Jr.

Cancer Immunol Immunother. 2017 Jan;66(1):33-43. doi: 10.1007/s00262-016-1908-4. Epub 2016 Oct 21.

6.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. doi: 10.1007/s00262-016-1880-z. Epub 2016 Aug 13.

7.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13.

8.

Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.

Ladoire S, Senovilla L, Enot D, Ghiringhelli F, Poirier-Colame V, Chaba K, Erdag G, Schaefer JT, Deacon DH, Zitvogel L, Slingluff CL Jr, Kroemer G.

Oncoimmunology. 2016 Mar 16;5(6):e1160193. doi: 10.1080/2162402X.2016.1160193. eCollection 2016 Jun.

9.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW.

Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.

10.

TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Mauldin IS, Wang E, Deacon DH, Olson WC, Bao Y, Slingluff CL Jr.

Int J Cancer. 2015 Sep 15;137(6):1386-96. doi: 10.1002/ijc.29515. Epub 2015 May 29.

11.

MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.

Zarling AL, Obeng RC, Desch AN, Pinczewski J, Cummings KL, Deacon DH, Conaway M, Slingluff CL Jr, Engelhard VH.

Cancer Res. 2014 Dec 1;74(23):6784-95. doi: 10.1158/0008-5472.CAN-14-0043. Epub 2014 Oct 8.

12.

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.

Dillon PM, Olson WC, Czarkowski A, Petroni GR, Smolkin M, Grosh WW, Chianese-Bullock KA, Deacon DH, Slingluff CL Jr.

J Immunother Cancer. 2014 Jul 15;2:23. doi: 10.1186/2051-1426-2-23. eCollection 2014.

13.

A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence.

Judge JM, Brill LB 2nd, Smith KT, Deacon DH, Patterson JW, Grosh WW, Jungbluth AA, Gnjatic S, Slingluff CL Jr.

Cancer Immunol Immunother. 2013 Aug;62(8):1327-34. doi: 10.1007/s00262-013-1433-7. Epub 2013 May 12.

14.

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr.

Cancer Res. 2012 Mar 1;72(5):1070-80. doi: 10.1158/0008-5472.CAN-11-3218. Epub 2012 Jan 19.

15.

The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.

Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL Jr.

J Immunother. 2012 Jan;35(1):78-88. doi: 10.1097/CJI.0b013e31823731a4.

16.

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.

Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr.

J Transl Med. 2010 Aug 20;8:79. doi: 10.1186/1479-5876-8-79.

17.

The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines.

Deacon DH, Hogan KT, Swanson EM, Chianese-Bullock KA, Denlinger CE, Czarkowski AR, Schrecengost RS, Patterson JW, Teague MW, Slingluff CL Jr.

BMC Cancer. 2008 Dec 4;8:360. doi: 10.1186/1471-2407-8-360.

18.

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK.

J Clin Oncol. 2008 Oct 20;26(30):4973-80. doi: 10.1200/JCO.2008.17.3161. Epub 2008 Sep 22.

19.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P.

J Clin Oncol. 2004 Nov 15;22(22):4474-85.

PMID:
15542798
20.

Competition among peptides in melanoma vaccines for binding to MHC molecules.

Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, Deacon DH, Engelhard VH, Slingluff CL Jr.

J Immunother. 2004 Nov-Dec;27(6):425-31.

PMID:
15534486
21.

Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.

Thompson LW, Hogan KT, Caldwell JA, Pierce RA, Hendrickson RC, Deacon DH, Settlage RE, Brinckerhoff LH, Engelhard VH, Shabanowitz J, Hunt DF, Slingluff CL Jr.

J Immunother. 2004 May-Jun;27(3):177-83.

PMID:
15076134
22.

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH.

J Clin Oncol. 2003 Nov 1;21(21):4016-26.

PMID:
14581425
23.

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL Jr.

Int J Cancer. 2001 Jun 1;92(5):703-11.

24.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.

Cancer Immunol Immunother. 2000 Mar;48(12):661-72.

PMID:
10752474
26.

Growth factor modulated calmodulin-binding protein stimulates nuclear DNA synthesis in hemopoietic progenitor cells.

Reddy GP, Reed WC, Deacon DH, Quesenberry PJ.

Biochemistry. 1994 May 31;33(21):6605-10.

PMID:
8204597
28.

Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA+Lin- murine hematopoietic progenitors.

Lowry PA, Zsebo KM, Deacon DH, Eichman CE, Quesenberry PJ.

Exp Hematol. 1991 Oct;19(9):994-6.

PMID:
1893977
29.

Multifactor stimulation of megakaryocytopoiesis: effects of interleukin 6.

Quesenberry PJ, McGrath HE, Williams ME, Robinson BE, Deacon DH, Clark S, Urdal D, McNiece IK.

Exp Hematol. 1991 Jan;19(1):35-41.

PMID:
1703492
30.

Further studies on growth factor production by the TC-1 stromal cell line: pre-B stimulating activity.

Woodward TA, McNiece IK, Witte PL, Bender P, Crittenden R, Temeles DS, Robinson BE, Baber GB, Deacon DH, Isakson PC, et al.

Blood. 1990 Jun 1;75(11):2130-6.

PMID:
1693296
31.

Stromal regulation of hematopoiesis.

Quesenberry PJ, Mcniece IK, McGrath HE, Temeles DS, Baber GB, Deacon DH.

Ann N Y Acad Sci. 1989;554:116-24. No abstract available.

PMID:
2544121

Supplemental Content

Loading ...
Support Center